Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3

 
• By John Davis
  
GreenPawn
Improved survival is a key measure for regulators and patients alike. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category